Role of vaginal pallor reaction in predicting late vaginal stenosis after high-dose-rate brachytherapy in treatment-naive patients with cervical cancer / 부인종양

OBJECTIVE: To assess actual rates of late vaginal stenosis and identify predisposing factors for complications among patients with previously untreated cervical cancer following high-dose-rate brachytherapy. METHODS: We performed longitudinal analyses of 57 patients using the modified Dische score at 6, 12, 18, 24, 36, and 60 months after treatment, which consisted of 15 interstitial brachytherapys and 42 conventional intracavitary brachytherapys, with a median follow-up time of 36 months (range, 6 to 144 months). RESULTS: More than half of the patients developed grade 1 (mild) vaginal stenosis within the first year of follow-up, and grade 2 (97.5%, moderate) to grade 3 (severe) stenosis gradually increased with time. Actual stenosis rates for grade 1, 2, and 3 were 97.5% (95% confidence interval [CI], 92.7 to 97.5), 60.7% (95% CI, 42.2 to 79.3), and 7.4% (95% CI, 0 to 18.4) at 3 years after treatment. Pallor reaction grade 2-3 at 6 months was only a statistically significant predisposing factor for grade 2-3 late vaginal stenosis 3 years or later with a hazard ratio of 3.48 (95% CI, 1.32 to 9.19; p=0.018) by a multivariate Cox proportional hazard model. Patients with grade 0-1 pallor reaction at 6 months showed a grade > or =2 vaginal stenosis rate of 53%, whereas the grade 2-3 pallor reaction group achieved a grade > or =2 vaginal stenosis rate at 3 years at 100% (p=0.001). CONCLUSION: High-dose-rate brachytherapy was associated with high incidence of late vaginal stenosis. Pallor reaction grade 2-3 at 6 months was predictive of late grade 2-3 vaginal stenosis at 3 years after treatment. These findings should prove helpful for patient counseling and preventive intervention.

Resultados da associação de braquiterapia de alta taxa de dose à teleterapia no câncer da próstata / Results of the association of high dose-rate brachytherapy with external beam irradiation in prostate cancer

INTRODUÇÃO: Braquiterapia de alta taxa de dose (BATD) para o câncer de próstata pode ser uma boa opção para escalonamento de dose, como um reforço de dose, associada à radioterapia externa, principalmente se não há disponibilidade de radioterapia tridimensional conformada ou tecnologia mais avançada. OBJETIVOS: Neste trabalho, analisaram-se os resultados e as toxicidades de um reforço de dose com BATD prévio à radioterapia externa convencional ou tridimensional conformada em pacientes portadores de câncer localizado da próstata. Fatores prognósticos relacionados à sobrevida livre de doença, além de toxicidade do tratamento também foram estudados. MÉTODOS: Estudo retrospectivo de 403 pacientes com adenocarcinoma localizado da próstata tratados entre dezembro de 2000 e março de 2004, que receberam 3 esquemas de fracionamento distintos de BATD de acordo com o seu grupo de risco: três frações de 5,5 a 6 Gy, 6 a 6,5 Gy ou 6,5 a 7 Gy, para baixo, médio ou alto risco, respectivamente, em um único implante, no decorrer de 24h de internação. A radioterapia externa convencional ou conformada compreendeu dose de 45 Gy na próstata e vesículas seminais. Foram realizadas análises uni e multivariada para avaliação dos fatores prognósticos relacionados à sobrevida livre de falha bioquímica e toxicidades. RESULTADOS: A idade mediana dos pacientes foi de 68 anos, com PSA médio de 9g/ml, peso prostático médio de 35 cc. Grau histológico de Gleason igual a 6 ocorreu em 43% dos casos, estádio menor do que T2c em 97%, presença de nódulo prostático em 49%; 11% dos pacientes apresentaram história de ressecção transuretral e 16% obstrução urinária prévias. No grupo de baixo risco foram classificados 36.1% dos pacientes, 42.8% no grupo de risco intermediário e 21.1% foram considerados de alto risco. Hormonioterapia neoadjuvante por até 6 meses foi utilizada em 64% dos casos e teleterapia conformada em 19%. O seguimento médio foi de 50 meses (mediano de 48,4 meses), variando de 24 a 113...

INTRODUCTION: high dose-rate brachytherapy (HDR) for prostate cancer may be a nice treatment option for dose escalation as a boost, when associated to external beam irradiation, mainly if 3D conformal or more advanced technology is not available. PURPOSE: this study analyzes the results and toxicities of HDR brachytherapy boost prior to external beam radiotherapy with 2D or 3D conformal irradiation in patients with localized prostate cancer. Prognostic factors associated to overall and disease-free survival, as well as to treatment related toxicity were also studied. METHODS: A retrospective study of 403 patients with localized prostate adenocarcinoma treated between December 2000 and March 2004 was performed. According to the risk group, three fractions of HDR brachytherapy were delivered in the course of 24 hours, with a single implant: 5.5 to 6 Gy per fraction for low risk, 6 to 6.5 Gy per fraction for intermediate risk, and 6.5 to 7 Gy per fraction for high risk patients. The interval between fractions was of at least 6 hours. Conventional 2D or 3D conformal external beam irradiation was delivered to the prostate and seminal vesicles with 25 fractions of 1.8Gy (45Gy), about 2 weeks after brachytherapy. Multivariate analysis was done to evaluate unfavorable prognostic factors for biochemical failure free survival (BFFS). RESULTS: Patients presented a median age of 68 years, mean PSA of 9g/ml, and average prostate weight of 35 cc. Gleason score was equal to 6 in 43% of the cases, and 97% of the cases were at a stage lower than T2c. Prostate nodules were present in 49% of the patients; prior history of transurethral resection or urinary obstruction was present in 11% and 16% of the patients, respectively. There were 36.1% patients in the low risk group, 42.8% in the intermediate, and 21.1% in the high risk groups, respectively. Up to six months of neoadjuvant hormone therapy was used in 64% of the cases. External beam radiation was delivered with 3D...

Endocavitary radiotherapy in carcinoma oesophagus.

Radiation therapy is often used in an attempt to palliate or cure oesophageal neoplasms. However, the radiation tolerance of the normal structures around the oesophagus (heart, lung and spinal cord) restricts the radiation dose that can be delivered. We used a nasogastric catheter to deliver High Dose Intra-luminal Iridium-192 irradiation for carcinoma of the oesophagus using HDR-Varisource machine. This technique for treatment of carcinoma of the oesophagus can help overcome the dose restraints. The external beam radiation dose was about 46 Gy and the intra luminal dose was 5 Gy at 1 cm from central axis. These after loading procedures are simple, fast and accurate and can be used to boost external radiation therapy doses. Since the intra luminal boost delivers a high-localized dose with little side effects, this simple technique should be used to obtain palliation, delay tumour progression, reduce overall treatment time and attempt to improve survival in patients with oesophageal neoplasm. Intra luminal brachytherapy helps achieve good palliation in these neoplasms.

Postoperative radiotherapy with high dose rate iridium 192 mould for prevention of earlobe keloids.

BACKGROUND: A 50% to 80% recurrence rate of earlobe keloids can occur following a simple excision. Many modalities, including radiotherapy, have been suggested to reduce the postoperation recurrence. OBJECTIVE: The aim of the present study was to determine the efficacy of postoperative radiotherapy by a high dose rate Iridium 192 mould in the prevention of earlobe keloids recurrence. MATERIAL AND METHOD: Between March 1999 and March 2003, 22 patients with 24 earlobe keloids were treated by radiotherapy immediately following surgical excision. A dose of 15 Gray in 3 fractions was delivered at a point placed 5 mm from the axis of the Iridium sources. RESULTS: From the 22 patients with 24 keloids who were treated, 15 patients with 16 keloids were followed for a minimum of 6 months. Recurrence occurred in two keloids (12.5%). There were no severe adverse effects. CONCLUSION: Postoperative radiotherapy by high dose rate Iridium 192 mould was an effective prevention of earlobe keloids recurrence. It was well tolerated and did not present any significant side effects.

Dose uniformity assessment of intraluminal brachytherapy using HDR 192Ir stepping source.

PURPOSE: The aim of this study is to achieve dose uniformity for intraluminal implants by assessment of dose distributions for single catheter generated by using various combinations of source stopping spacing and optimization mode. MATERIALS AND METHODS: A dose distribution was generated using HDR 192Ir stepping source on single straight catheter of fixed length used for Intraluminal brachytherapy. The various combinations of source position spacing and optimization mode were used and these dose distributions were evaluated by using three different parameters. The source position spacings were 0.2, 0.5, 1.0, 1.4, 2.0, 2.5, 3.0 and 3.3 cm. Three different optimization modes that compute the source stopping times along the catheter were used. The parameters used for assessment of dose distributions were statistical analysis of doses to dose reference points, area under natural dose-volume histogram and the dose non-uniformity ratio. RESULTS: None of the combinations of source position spacing and optimization mode was able to generate the desired optimum uniform dose distribution. However in a discrete manner, comparatively higher uniform dose distribution was found with short (0.2 cm) and longer (1.5 to 2.0 cm) source spacing. Optimization mode of Iterative correction was found to be suitable for the single catheter used in intraluminal brachytherapy. CONCLUSION: The applicator dimension and irradiation target volume should be taken in to consideration while selecting either higher or smaller source position spacing for the single catheter intraluminal brachytherapy. The Anisotropy factor of the source has some role in the variation of the dose uniformity over the target volume.

Survival Benefits of Lung Cancer Patients Undergoing Laser and Brachytherapy

We aimed to compare the duration of survival among subjects receiving brachytherapy (BT) in combination with Nd:YAG laser therapy (LT), and those receiving LT or BT alone. The medical records of subjects who received endobronchial treatment for unresectable tracheobronchial malignancies between January 1997 and December 1999 in a single center were reviewed retrospectively. A total of 80 patients were evaluated. The overall symptomatic response rate after treatment was 86.5%. Median survival durations for the LT, BT, and combined therapy (CT) group were 111, 115, and 264 days, respectively. The survival duration was significantly longer in the CT group than in the BT group (p=0.0078), but the difference was not statistically significant between the CT and the LT group. The bronchoscopic finding of endobronchial polypoid lesion was associated with a longer survival time than extraluminal with compression type (p=0.0023) by univariate analysis. Other factors associated with the better prognosis included hemoglobin > or = 12.5 g/dL, serum albumin level > or =37 g/L, and BT dose > or = 15 Gy at 1 cm distance. Of these factors, specific bronchoscopic findings, serum albumin level, CT modality, and dose of BT retained statistical significance in multivariate analysis. In conclusion, combined LT and BT is associated with increased patient survival compared with BT alone. Combined therapy may improve survival time in selected patients with endobronchial malignancies.

Tratamento do câncer do endométrio com braquiterapia de alta taxa de dose / Treatment of endometrium neoplasm with high dose rate brachytherapy

Cento e quatro pacientes com histologia comprovada de carcinoma do endométrio foram tratadas desde a instalaçao da BATD no Departamento, em 1991. A idade mediana foi de 65,5 anos e o seguimento mediano de 38 meses. Noventa e cinco eram pós-menopausadas, sete peri-menopausadas e duas estavam na pré-menopausa. Dezesseis pacientes eram do estádio clínico (pós-cirúrgico) EC IA, sendo cinco com grau de diferenciaçao Gl, oito G2 e três G3. Trinta e quatro pacientes eram do EC IB, dez com grau de diferenciaçao Gl, 18 G2 e seis G3. Vinte e cinco eram do EC IC, sendo nove Gl, nove G2 e sete G3. Seis eram do EC IIA, duas Gl, três G2 e uma G3. Oito eram do EC IIB, uma Gl, três G2 e quatro G3. Nove eram do EC IIIA, duas Gl, cinco G2 e duas G3. Três eram do EC IIIB, sendo duas Gl e uma G2. Uma era EC IIIC G3 e duas eram IVA G3. Dependendo da extensao da doença, a cirurgia consistiu de pan-histerectomia (Histerectomia total mais salpingooforectomia bilateral), pan-histerectomia mais omentectomia ou Wertheim-Meigs. Todas as pacientes dos estádios clínicos IA e IB apresentam-se sem evidência de doença (SED). As do EC IC 24 estao SED e uma apresentou metástases (MAD). As do EC IIA, cinco estao SED e uma MAD. As do EC IIB, seis estao SED, uma com progressao de doença local (PDL) e uma foi a óbito (OPD). As do EC IIIA, sete estao SED, uma MAD e uma apresentou progressao de doença. As do EC IIIB l está SED e duas apresentam progressao de doença. A paciente IIIC está SED, dois meses após o tratamento, e as IVA se apresentam SED, três e quatro meses após o término do tratamento. Oito pacientes apresentaram complicaçoes leves de tratamento Os resultados sao semelhantes aos dos tratamentos com braquiterapia de baixa taxa de dose, tanto em sobrevida como em complicaçao, com a vantagem de ser realizado em regime ambulatorial , sem os inconvenientes de uma internaçao hospitalar.